![Ilka Wicke](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ilka Wicke
Inversor de Capital Privado en
Boehringer Ingelheim (Venture Capital)
.
Perfil
Ilka Wicke is an Investment Manager & Director at Boehringer Ingelheim (Venture Capital) since 2010.
She is also a Director at Pcovery ApS.
Previously, she worked as a Licensing Director at Boehringer Ingelheim GmbH, and as a Director at PROMETHERA Biosciences SA, Cardior Pharmaceuticals GmbH, and AgomAb Therapeutics NV.
Dr. Wicke holds a doctorate degree from Johann Wolfgang Goethe-Universität Frankfurt am Main.
Cargos activos de Ilka Wicke
| Empresas | Cargo | Inicio |
|---|---|---|
Boehringer Ingelheim (Venture Capital)
 Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm targets companies operating in groundbreaking innovation including cancer, regenerative medicine, auto-immunity indications, digital solutions and infectious disease. It participaotes in seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes seat on the board of directors. | Inversor de Capital Privado | 01/01/2010 |
Antiguos cargos conocidos de Ilka Wicke.
| Empresas | Cargo | Fin |
|---|---|---|
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes cell therapy products to treat liver diseases | Director/Miembro de la Junta | 06/04/2018 |
| AGOMAB THERAPEUTICS NV | Director/Miembro de la Junta | - |
Cardior Pharmaceuticals GmbH
 Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Engages in discovery and development of therapies that target RNA as a means to prevent, repair & reverse diseases of the hearts | Director/Miembro de la Junta | - |
Boehringer Ingelheim GmbH
 Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Manufactures and wholesales animal health & pharmaceutical products | Corporate Officer/Principal | - |
Pcovery ApS
 Pcovery ApS Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of invasive fungal infections | Director/Miembro de la Junta | - |
Formación de Ilka Wicke.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
6
Relaciones de 1er grado
7
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 7 |
|---|---|
Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Manufactures and wholesales animal health & pharmaceutical products | Health Technology |
Johann Wolfgang Goethe-Universität Frankfurt am Main
 Johann Wolfgang Goethe-Universität Frankfurt am Main Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes cell therapy products to treat liver diseases | Health Technology |
Boehringer Ingelheim (Venture Capital)
Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm targets companies operating in groundbreaking innovation including cancer, regenerative medicine, auto-immunity indications, digital solutions and infectious disease. It participaotes in seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes seat on the board of directors. | Finance |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of invasive fungal infections | Health Technology |
Cardior Pharmaceuticals GmbH
Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Engages in discovery and development of therapies that target RNA as a means to prevent, repair & reverse diseases of the hearts | Health Technology |
AgomAb Therapeutics NV
 AgomAb Therapeutics NV BiotechnologyHealth Technology Develops molecular therapies for regeneration of damaged tissues | Health Technology |
- Bolsa de valores
- Insiders
- Ilka Wicke
Elige MarketScreener 
